BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

hGH-CTP: Phase II data

Top-line data from an open-label, dose-ranging, international Phase II trial in 39 patients showed that a single weekly injection of hGH-CTP containing 30%, 40% or 100% of the equivalent cumulative commercial dose that a patient would normally inject each day over the course of 7 days led to average IGF-1 levels that were within the normal therapeutic range, +/- 2 standard deviations from the...

Read the full 296 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >